Hepatic fibrosis - therapeutic strategies.
Schuppan
D
D
Medizinische Klinik I, Universität Erlangen-Nürnberg, Deutschland. detlef.schuppan@med1.med.uni-erlangen.de
Strobel
D
D
Hahn
E G
EG
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002756:Cholagogues and Choleretics / Q000627:therapeutic use*; D016326:Extracellular Matrix Proteins / Q000096:biosynthesis / Q000187:drug effects; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000378:metabolism; D008106:Liver Cirrhosis, Experimental / Q000188:drug therapy / Q000378:metabolism; D010431:Pentoxifylline / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D012176:Retinoids / Q000627:therapeutic use; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D002756:Cholagogues and Choleretics; D016326:Extracellular Matrix Proteins; D010726:Phosphodiesterase Inhibitors; D012176:Retinoids; D014580:Ursodeoxycholic Acid; D007372:Interferons; D010431:Pentoxifylline